Skip to content

Research at St Andrews

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

Research output: Contribution to journalArticle

Abstract

Background: Results of small trials indicate that fluoxetine might improve functional outcomes after stroke. The FOCUS trial aimed to provide a precise estimate of these effects.
Methods: FOCUS was a pragmatic, multicentre, parallel group, double-blind, randomised, placebo-controlled trial done at 103 hospitals in the UK. Patients were eligible if they were aged 18 years or older, had a clinical stroke diagnosis, were enrolled and randomly assigned between 2 days and 15 days after onset, and had focal neurological deficits. Patients were randomly allocated fluoxetine 20 mg or matching placebo orally once daily for 6 months via a web-based system by use of a minimisation algorithm. The primary outcome was functional status, measured with the modified Rankin Scale (mRS), at 6 months. Patients, carers, health-care staff, and the trial team were masked to treatment allocation. Functional status was assessed at 6 months and 12 months after randomisation. Patients were analysed according to their treatment allocation. This trial is registered with the ISRCTN registry, number ISRCTN83290762.
Findings: Between Sept 10, 2012, and March 31, 2017, 3127 patients were recruited. 1564 patients were allocated fluoxetine and 1563 allocated placebo. mRS data at 6 months were available for 1553 (99·3%) patients in each treatment group. The distribution across mRS categories at 6 months was similar in the fluoxetine and placebo groups (common odds ratio adjusted for minimisation variables 0·951 [95% CI 0·839-1·079]; p=0·439). Patients allocated fluoxetine were less likely than those allocated placebo to develop new depression by 6 months (210 [13·43%] patients vs 269 [17·21%]; difference 3·78% [95% CI 1·26-6·30]; p=0·0033), but they had more bone fractures (45 [2·88%] vs 23 [1·47%]; difference 1·41% [95% CI 0·38-2·43]; p=0·0070). There were no significant differences in any other event at 6 or 12 months.
Interpretation: Fluoxetine 20 mg given daily for 6 months after acute stroke does not seem to improve functional outcomes. Although the treatment reduced the occurrence of depression, it increased the frequency of bone fractures. These results do not support the routine use of fluoxetine either for the prevention of post-stroke depression or to promote recovery of function.
Close

Details

Original languageEnglish
Pages (from-to)265-274
Number of pages10
JournalLancet
Volume393
Issue number10168
Early online date5 Dec 2018
DOIs
Publication statusPublished - 19 Jan 2019

    Research areas

  • Administration, Oral, Aged, Antidepressive agents, Depression/epidemiology, Double-blind method, Female, Fluoxetine/administration & dosage, Fractures, bone/chemically induced, Humans, Male, Middle aged, Recovery of function, Stroke rehabilitation/methods, Surveys and questionnaires, Second-generation/administration & dosage

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Do statins have an effect on depressive symptoms? A systematic review and meta-analysis

    Yatham, M. S., Yatham, K. S., Ravindran, A. V. & Sullivan, F., 2 Jul 2019, In : Journal of Affective Disorders. 257, p. 55-63 9 p.

    Research output: Contribution to journalArticle

  2. Unconditional and conditional monetary incentives to increase response to mailed questionnaires: a randomized controlled study within a trial (SWAT)

    Young, B., Bedford, L., das Nair, R., Gallant, S., Littleford, R., Robertson, J. F. R., Schembri, S., Sullivan, F. M., Vedhara, K., Kendrick, D. & ECLS study team, 22 Jul 2019, In : Journal of Evaluation in Clinical Practice. Early View

    Research output: Contribution to journalArticle

  3. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

    RESTART Collaboration & Sullivan, F., 29 Jun 2019, In : Lancet. 393, 10191, p. 2613-2623 11 p.

    Research output: Contribution to journalArticle

  4. The impact of treatment adherence for patients with diabetes and hypertension on cardiovascular disease risk: a protocol for a retrospective cohort study, 2008-2018

    Su, M., Haldane, V., Upshur, R., Sullivan, F., Garda, F. L. A., Greiver, M. & Wei, X., 31 May 2019, In : JMIR Research Protocols. 8, 5, 11 p., e13571.

    Research output: Contribution to journalArticle

  5. Factors associated with recruitment to randomised controlled trials in general practice: protocol for a systematic review

    Moffat, K. R., Cannon, P., Shi, W. & Sullivan, F., 10 May 2019, In : Trials. 20, 4 p., 66.

    Research output: Contribution to journalArticle

Related by journal

  1. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

    RESTART Collaboration & Sullivan, F., 29 Jun 2019, In : Lancet. 393, 10191, p. 2613-2623 11 p.

    Research output: Contribution to journalArticle

  2. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial

    Thwaites, G. E., Scarborough, M., Szubert, A., Nsutebu, E., Tilley, R., Greig, J., Wyllie, S. A., Wilson, P., Auckland, C., Cairns, J., Ward, D., Lal, P., Guleri, A., Jenkins, N., Sutton, J., Wiselka, M., Armando, G-R., Graham, C., Chadwick, P. R., Barlow, G. & 18 othersGordon, N. C., Young, B., Meisner, S., McWhinney, P., Price, D. A., Harvey, D., Nayar, D., Jeyaratnam, D., Planche, T., Minton, J., Hudson, F., Hopkins, S., Williams, J., Török, M. E., Llewelyn, M. J., Edgeworth, J. D., Walker, A. S. & United Kingdom Clinical Infection Research Group (UKCIRG), 17 Feb 2018, In : Lancet. 391, 10121, p. 668-678 11 p.

    Research output: Contribution to journalArticle

  3. Management of multimorbidity using a patient-centred care model: a pragmatic cluster-randomised trial of the 3D approach

    Salisbury, C., Man, M-S., Bower, P., Guthrie, B., Chaplin, K., Gaunt, D. M., Brookes, S., Fitzpatrick, B., Gardner, C., Hollinghurst, S., Lee, V., McLeod, J., Mann, C., Moffat, K. R. & Mercer, S. W., 7 Jul 2018, In : Lancet. 392, 10141, p. 41-50

    Research output: Contribution to journalArticle

  4. Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial

    Azuara-Blanco, A., Burr, J., Ramsay, C., Cooper, D., Foster, P. J., Friedman, D. S., Scotland, G., Javanbakht, M., Cochrane, C., Norrie, J. & EAGLE study group, 1 Oct 2016, In : Lancet. 388, 10052, p. 1389-1397 9 p.

    Research output: Contribution to journalArticle

ID: 258532510